Heart failure progression shares multiple molecular signaling pathways with cancer biology, suggesting that targeted therapies addressing specific phenotypic endpoints and molecular checkpoints may offer new treatment strategies.
Pathways for surrogate failing heart phenotypesChamber dilation: diverse cytoskeletal pathways.Changes in organ size, shape, and histological phenotype are central features of both tumorigenesis and heart failure.Chronic increases
Hoshijima et al. (Mon,) conducted a review in Heart failure. Heart failure progression shares multiple molecular signaling pathways with cancer biology, suggesting that targeted therapies addressing specific phenotypic endpoints and molecular checkpoints may offer new treatment strategies.